Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Nimbus Announces Expansion of Its Immunology Drug Discovery Pipeline
Anagenex and Nimbus Announce a Multi-Target Collaboration
Nimbus Presents Positive Data from Clinical Trial of HPK1 Inhibitor
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
Takeda has revealed the data that persuaded it to pay $4 billion for Nimbus Therapeutics’ TYK2 inhibitor. The highest dose completely cleared psoriasis in one-third of patients, adding weight to claims that the candidate is an improvement on Bristol Myers Squibb’s rival drug Sotyktu.
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions. The agreement had been announced on December 13, 2022: “Takeda to Acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary”
Nimbus Therapeutics, the biotechnology company that just signed one of the most lucrative deals for an unapproved drug in industry history, started out as an experiment in financial engineering.
Dec 13 (Reuters) - Takeda Pharmaceutical (4502.T) will buy U.S.-based Nimbus Therapeutics' experimental psoriasis drug for up to $6 billion, the Japanese drugmaker said on Tuesday, as it looks to cut reliance on treatments facing loss of patents.